secwatch.observer — SEC 8-K summary
======================================

Issuer:     Serina Therapeutics, Inc. (SER)
CIK:        0001708599
Form:       8-K
Filed at:   2025-12-10T23:59:59+00:00
Accession:  0001708599-25-000138
Event type: regulatory
Sentiment:  neutral
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Serina submits complete response to FDA clinical hold for SER-252 Parkinson's program
--------------------------------------------------------------------------------

- Complete response submitted Dec 9, 2025, addressing FDA's clinical hold on SER-252 related to trehalose excipient.
- Submission includes detailed data package on trehalose as subcutaneous excipient and revised protocol for SAD phase.
- FDA clinical hold does not involve apomorphine drug substance, mechanism of action, enFuse device, or 505(b)(2) pathway.
- Global site start-up continues; first-patient-in for Phase 1b registrational study targeted for Q1 2026, subject to hold resolution.
- Company acknowledges FDA's engagement and expects SAD phase initiation in Q1 2026 pending regulatory and ethics approvals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708599/000170859925000138/0001708599-25-000138-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708599/000170859925000138/ser-20251210xserinatofdare.htm
  HTML page:      https://secwatch.observer/filing/0001708599-25-000138

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer